Trusted by 100,000+ International Patients
CAR-T: United Arab Emirates vs United Kingdom
Cost, Quality & Recovery Compared
$200000
United Arab Emirates Starting Cost
$373000
United Kingdom Starting Cost
See how these top medical tourism destinations compare for CAR-T.
| Comparison Factor | United Arab Emirates | United Kingdom | Winner |
|---|---|---|---|
| Average Cost (in USD) | 200000 - 300000 | 373000 - 475000 | United Arab Emirates |
| Success Rate (Min and Max) | 65% – 85% response (indication dependent) | - | Both Equal |
| Advanced Technology | Advanced CAR-T therapy programmes available at leading UAE oncology centres supported by GMP-compliant cell processing labs, apheresis units, molecular diagnostics, and specialised haematology-oncology ICUs equipped to manage complications such as CRS and ICANS. | - | Both Equal |
| JCI Accredited Hospitals | 25+ internationally accredited hospitals | - | Both Equal |
| Visa Process | Medical Visa / Tourist Visa / eVisa (2–5 working days) | - | Both Equal |
| Hospital Stay (typical) | 14–28 days | - | Both Equal |
| Patient Journey Complexity | Very High (complex personalised immunotherapy involving cell harvesting, genetic modification, conditioning chemotherapy, and intensive monitoring) | - | Both Equal |
*Costs are estimates and may vary based on hospital, complexity, and package inclusions. See detailed cost breakdown below
Understand exactly where your money goes. Both countries offer all-inclusive packages, but here's how the costs typically break down.
Best for Budget-Conscious Patients
Offered Package Price (Additional Cost Excluded)
Top Hospitals: Thumbay University Hospital, Ajman , Kings College Hospital Dubai
Best for Flexible Donor Requirements
Offered Package Price (Additional Cost Excluded)
Top Hospitals: The London Clinic
Want a personalized cost estimate based on your specific condition?
Get Your Free QuoteBoth United Arab Emirates and United Kingdom maintain world-class healthcare standards with internationally accredited hospitals and highly trained medical professionals.
The United Arab Emirates hosts internationally accredited hospitals, including JCI-accredited oncology centres with advanced cell therapy programmes and adherence to global quality standards.
Leading oncology centres report strong CAR-T therapy outcomes supported by advanced diagnostics, experienced haematology-oncology teams, and structured multidisciplinary care pathways.
CAR-T therapy is regulated by national health authorities such as the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority (DHA), ensuring compliance with international safety, ethical, and clinical governance standards.
The United Kingdom offers highly regulated healthcare through NHS and private hospitals accredited by the Care Quality Commission (CQC) and aligned with international quality standards, with select centres holding JCI accreditation.
CAR-T therapy outcomes in the UK are strong in approved indications such as lymphoma and leukaemia, supported by experienced multidisciplinary teams and access to advanced therapies and clinical trials.
CAR-T therapies are strictly regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) under UK law, aligned with advanced therapy medicinal product (ATMP) guidelines, ensuring high safety, efficacy, and monitoring standards.
| Quality Metric | United Arab Emirates | United Kingdom |
|---|---|---|
Accredited Hospitals | 25+ | 5–7 |
Average Success Rate | 65% – 85% response | 60% – 90% response (indication dependent) |
Post‑op / 1‑year outcome signal | Indication-dependent | Strong remission rates in approved indications like lymphoma and leukaemia |
Top Speciality Hubs | Dubai, Abu Dhabi | London, Manchester, Birmingham |
Both countries have highly qualified and experienced medical specialists trained at premier institutions worldwide. Here's what sets them apart.
Haematologists and oncology specialists trained in CAR-T therapy, stem cell transplantation, and advanced immunotherapy protocols with international exposure.
Specialised cancer centres manage complex haematological malignancies with multidisciplinary tumour boards and growing experience in CAR-T and cellular therapies.
Highly specialised haematologists and oncologists trained in CAR-T therapy, immunotherapy, and stem cell transplantation
High experience in selected centres with established CAR-T programs and clinical trial participation
All surgeons listed on Medigence are verified for their medical license, board certifications, hospital affiliations, and patient outcomes. We conduct background checks and regularly update our database to ensure you're connected with the best medical professionals.
Beyond medical excellence, your comfort during treatment matters. Compare the patient experience at top hospitals in both destinations.
World-class hospitals, exceptional value
Advanced oncology hospitals equipped with GMP-compliant laboratories, apheresis units, specialised haematology wards, transplant units, and ICUs designed for managing immunotherapy-related complications.
Luxury healthcare experience
Advanced oncology and haematology centres with GMP-certified labs, apheresis units, cellular therapy labs, ICU support, and integrated CAR-T treatment pathways
Plan your medical journey with confidence. Here's everything you need to know about travel, visas, and accommodation in both countries.
We provide end-to-end travel assistance including visa facilitation, airport pickups, hotel bookings near your hospital, and local support throughout your stay. Our patient coordinators handle all logistics so you can focus on recovery.
Understanding the recovery process helps you plan better. Here's what to expect after CAR-T in both countries.
Patients usually remain in the hospital for close monitoring after CAR-T cell infusion to manage possible side effects such as cytokine release syndrome and neurological symptoms.
Patients are advised to remain near the treatment centre for regular monitoring, blood tests, and immediate management of any complications that arise.
Once the patient’s condition stabilises and doctors confirm the progress of recovery, they can safely travel back to their home country.
The immune system gradually rebuilds during this period as the modified CAR-T cells continue to target and eliminate cancer cells.
In-person follow-ups recommended at 3, 6, 12 months. Telemedicine available.
Patients usually remain in the hospital for close monitoring after CAR-T cell infusion to manage possible side effects such as cytokine release syndrome and neurological symptoms.
Patients are advised to remain near the treatment centre for regular monitoring, blood tests, and immediate management of any complications that arise.
Once the patient’s condition stabilises and doctors confirm the progress of recovery, they can safely travel back to their home country.
The immune system gradually rebuilds during this period as the modified CAR-T cells continue to target and eliminate cancer cells.
Comprehensive telemedicine follow-up program. Return visits at 6, 12 months if possible.
CAR-T recipients require lifelong immunosuppressant medications. Ensure you have a plan for obtaining these medications and regular blood monitoring in your home country before traveling abroad for surgery.
Every medical procedure carries risks. We believe in complete transparency so you can make a fully informed decision about your CAR-T journey.
An immune reaction after CAR-T infusion causes fever, low blood pressure, and flu-like symptoms.
Temporary neurological symptoms such as confusion, headache, or speech difficulty may occur.
The weakened immune system after therapy increases the risk of bacterial or viral infections.
Reduced levels of red cells, white cells, or platelets may increase the risk of infection or bleeding.
Side effects may occur due to supportive medications, such as chemotherapy or immune-related treatments, used during CAR-T therapy.
The right choice depends on your specific situation. Here's a clear guide to help you decide which destination aligns with your needs.
Patients with relapsed or treatment-resistant blood cancers, such as leukaemia or lymphoma, who are eligible for advanced cellular immunotherapy like CAR-T treatment.
Patients with relapsed or treatment-resistant blood cancers, such as leukaemia or lymphoma, who are eligible for advanced cellular immunotherapy like CAR-T treatment.
Our medical tourism experts can analyze your case and recommend the best destination based on your medical history and budget.
Follow this step-by-step framework to make the right choice for your CAR-T journey.
Assess the type and stage of cancer to determine eligibility and urgency for CAR-T therapy.
Plan the overall cost, including treatment, travel, accommodation, and unexpected medical expenses.
Ensure you can stay near the treatment centre for monitoring during the early recovery period.
Provide detailed reports in advance so specialists can evaluate eligibility and create a treatment plan.
Arrange continued monitoring and coordination with local doctors for recovery and long-term outcomes.
Let our medical tourism experts guide you through the process. We'll help you:
No obligation • Free consultation • Response within 24 hours
Surgical Oncologist
15 Years of Experience
Dr. Prateek Varshney is a renowned Surgical Oncologist. He has experience of more than 15+ years in surgical Oncology. He is currently practicing as a consultant at Metro Mass Hospital and Cancer Institute. He was also previously associated as a consultant with Sir Ganga Ram Hospital and as a professor at Gujarat Cancer Research Institute. View More
